BioCentury | Oct 17, 2019
Financial News

Innate gains dual listing, tops off fund-raise with private placement

With the $68.8 million raised through a NASDAQ listing and concurrent private placement, Innate plans to commercialize its sole approved cancer therapy and advance its clinical and preclinical pipeline. Innate Pharma S.A. (Euronext:IPH; NASDAQ:IPHA) gained...
BioCentury | Oct 26, 2018
Company News

AstraZeneca gets rights, options to Innate immuno-oncology therapies

AstraZeneca plc (LSE:AZN; NYSE:AZN) expanded its next generation immuno-oncology pipeline on Oct. 23, gaining rights and options to a basket of therapies from Innate Pharma S.A. (Euronext:IPH). In return, Innate gained U.S. and European commercialization...
BioCentury | Oct 23, 2018
Company News

AstraZeneca gets rights, options to basket of next-gen immuno-oncology therapies from Innate

AstraZeneca plc (LSE:AZN; NYSE:AZN) expanded its next generation immuno-oncology pipeline on Tuesday, gaining rights and options to a basket of therapies from Innate Pharma S.A. (Euronext:IPH). In return, Innate gained U.S. and European commercialization rights...
BioCentury | Jun 1, 2018
Clinical News

Innate reports Phase I data for monalizumab plus Imfinzi in CRC

Innate Pharma S.A. (Euronext:IPH) reported preliminary data from 37 evaluable patients with recurrent, metastatic, microsatellite-stable colorectal cancer (MSS-CRC) in an expansion portion of a Phase I trial showing that monalizumab (IPH2201) plus Imfinzi durvalumab from...
BioCentury | Jun 15, 2015
Company News

Novo Nordisk, J&J, Innate Pharma deal

...unit received an exclusive, worldwide license from Novo Nordisk to develop and commercialize anti-NKG2D ( NN8555...
...year, Novo discontinued R&D within inflammatory disorders, including NN8555. In 2012, Novo discontinued development of NN8555...
BioCentury | Jan 12, 2015
Clinical News

Anti-NKG2a: Phase Ib/II started

Innate Pharma began an open-label, German Phase Ib/II trial to evaluate 4 or 10 mg/kg IPH 2201 every 2 weeks for 4 doses in 43 patients with resectable stage III-IVa squamous cell carcinoma of the...
BioCentury | Feb 10, 2014
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/7 cls Fluidigm Corp. (NASDAQ:FLDM) Cowen Doug Schenkel Downgrade Market perform (from outperform) -4% $43.11 Schenkel raised his target to $45 from $42, saying...
BioCentury | Feb 10, 2014
Company News

Innate Pharma, Novo Nordisk deal

Novo Nordisk granted Innate worldwide development and commercialization rights to anti-NKG2a ( IPH 2201 ) in exchange for €2 million ($2.7 million) in cash and 600,000 Innate shares. The Innate shares are valued at €6 million ($8...
BioCentury | Feb 10, 2014
Clinical News

Anti-NKG2D: Phase II planned

...Nordisk disclosed in its 2013 earnings that it plans to resume Phase II testing of NN8555...
...The company could not be reached for details. In 2012, Novo Nordisk discontinued development of NN8555...
...Marseille, France Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Product: Anti-NKG2D ( NN8555 ) (formerly IPH 2301...
BioCentury | Dec 24, 2012
Finance

Highlights of weekly biotech stock moves

...off €0.05 to €2.14 last week when Novo Nordisk A/S (CSE:NVO; NYSE:NVO) discontinued development of anti-NKG2D...
Items per page:
1 - 10 of 20